Detection and quantitation of human papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients

Chih Ming Ho, Sien Sing Yang, Tsai Yen Chien, Shih Hung Huang, Cherng Jye Jeng, Shwu Fen Chang

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective. To prospectively evaluate the feasibility of detecting human papillomavirus (HPV) type 16, 18 and 52 DNA in the peripheral blood of patients with cervical cancer using real-time polymerase chain reaction (PCR) and to determine its prognostic importance. Methods. Blood and cervical swab specimens from 135 consecutive patients with 60 invasive cervical cancers, 10 microinvasions, 20 cervical intraepithelial neoplasias (CIN) III, 10 CIN II, 10 CIN I and 25 controls were collected and examined for HPV type 16, 18 and 52 DNA using real-time PCR to investigate the prevalence and viral load of HPV DNA at the time of diagnosis and during follow-up in patients with positive blood samples. Results. Of the 60 patients with invasive cervical cancer, 27% had positive test results for HPV DNA in blood samples in contrast to 0% of patients with microinvasions, CIN III, CIN II, CIN I and normal controls. The DNA detection rates of viral subtypes in blood samples of cervical cancer patients were 5% for HPV-16, 16.7% for HPV-18, 8.3% for HPV-52, 1.7% for both HPV-16 and HPV-18 and 1.7% for both HPV-18 and HPV-52, while the detection rates in cervical swab specimens were 36.2% for HPV-16, 15.5% for HPV-18 and 17.2% for HPV-52. During follow-up, 8 of 10 cervical cancer patients with viral DNA detected in blood within 3 months after treatment had recurrence, and a high percentage (87.5%, 7/8) of this recurrence involved distant metastases. Conclusions. In this study, real-time PCR detected HPV-16, -18 or -52 DNA in the peripheral blood of more than one-fourth of invasive cervical cancer patients. The association between risk of cancer recurrence and the amount of viral DNA detected in blood among cervical cancer patients after treatment is intriguing and deserves further investigation.

Original languageEnglish
Pages (from-to)615-621
Number of pages7
JournalGynecologic Oncology
Volume99
Issue number3
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Human papillomavirus 18
Human papillomavirus 16
Uterine Cervical Neoplasms
Cervical Intraepithelial Neoplasia
DNA
Real-Time Polymerase Chain Reaction
Viral DNA
Recurrence
Human Papillomavirus DNA Tests
Viral Load
Neoplasm Metastasis

Keywords

  • Cervical carcinoma
  • Cervical neoplasia
  • Metastasis
  • Microinvasion
  • Polymerase chain reaction

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Detection and quantitation of human papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients. / Ho, Chih Ming; Yang, Sien Sing; Chien, Tsai Yen; Huang, Shih Hung; Jeng, Cherng Jye; Chang, Shwu Fen.

In: Gynecologic Oncology, Vol. 99, No. 3, 12.2005, p. 615-621.

Research output: Contribution to journalArticle

Ho, Chih Ming ; Yang, Sien Sing ; Chien, Tsai Yen ; Huang, Shih Hung ; Jeng, Cherng Jye ; Chang, Shwu Fen. / Detection and quantitation of human papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients. In: Gynecologic Oncology. 2005 ; Vol. 99, No. 3. pp. 615-621.
@article{ad777bae2623444ab3dfcf3c330becdc,
title = "Detection and quantitation of human papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients",
abstract = "Objective. To prospectively evaluate the feasibility of detecting human papillomavirus (HPV) type 16, 18 and 52 DNA in the peripheral blood of patients with cervical cancer using real-time polymerase chain reaction (PCR) and to determine its prognostic importance. Methods. Blood and cervical swab specimens from 135 consecutive patients with 60 invasive cervical cancers, 10 microinvasions, 20 cervical intraepithelial neoplasias (CIN) III, 10 CIN II, 10 CIN I and 25 controls were collected and examined for HPV type 16, 18 and 52 DNA using real-time PCR to investigate the prevalence and viral load of HPV DNA at the time of diagnosis and during follow-up in patients with positive blood samples. Results. Of the 60 patients with invasive cervical cancer, 27{\%} had positive test results for HPV DNA in blood samples in contrast to 0{\%} of patients with microinvasions, CIN III, CIN II, CIN I and normal controls. The DNA detection rates of viral subtypes in blood samples of cervical cancer patients were 5{\%} for HPV-16, 16.7{\%} for HPV-18, 8.3{\%} for HPV-52, 1.7{\%} for both HPV-16 and HPV-18 and 1.7{\%} for both HPV-18 and HPV-52, while the detection rates in cervical swab specimens were 36.2{\%} for HPV-16, 15.5{\%} for HPV-18 and 17.2{\%} for HPV-52. During follow-up, 8 of 10 cervical cancer patients with viral DNA detected in blood within 3 months after treatment had recurrence, and a high percentage (87.5{\%}, 7/8) of this recurrence involved distant metastases. Conclusions. In this study, real-time PCR detected HPV-16, -18 or -52 DNA in the peripheral blood of more than one-fourth of invasive cervical cancer patients. The association between risk of cancer recurrence and the amount of viral DNA detected in blood among cervical cancer patients after treatment is intriguing and deserves further investigation.",
keywords = "Cervical carcinoma, Cervical neoplasia, Metastasis, Microinvasion, Polymerase chain reaction",
author = "Ho, {Chih Ming} and Yang, {Sien Sing} and Chien, {Tsai Yen} and Huang, {Shih Hung} and Jeng, {Cherng Jye} and Chang, {Shwu Fen}",
year = "2005",
month = "12",
doi = "10.1016/j.ygyno.2005.07.004",
language = "English",
volume = "99",
pages = "615--621",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Detection and quantitation of human papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients

AU - Ho, Chih Ming

AU - Yang, Sien Sing

AU - Chien, Tsai Yen

AU - Huang, Shih Hung

AU - Jeng, Cherng Jye

AU - Chang, Shwu Fen

PY - 2005/12

Y1 - 2005/12

N2 - Objective. To prospectively evaluate the feasibility of detecting human papillomavirus (HPV) type 16, 18 and 52 DNA in the peripheral blood of patients with cervical cancer using real-time polymerase chain reaction (PCR) and to determine its prognostic importance. Methods. Blood and cervical swab specimens from 135 consecutive patients with 60 invasive cervical cancers, 10 microinvasions, 20 cervical intraepithelial neoplasias (CIN) III, 10 CIN II, 10 CIN I and 25 controls were collected and examined for HPV type 16, 18 and 52 DNA using real-time PCR to investigate the prevalence and viral load of HPV DNA at the time of diagnosis and during follow-up in patients with positive blood samples. Results. Of the 60 patients with invasive cervical cancer, 27% had positive test results for HPV DNA in blood samples in contrast to 0% of patients with microinvasions, CIN III, CIN II, CIN I and normal controls. The DNA detection rates of viral subtypes in blood samples of cervical cancer patients were 5% for HPV-16, 16.7% for HPV-18, 8.3% for HPV-52, 1.7% for both HPV-16 and HPV-18 and 1.7% for both HPV-18 and HPV-52, while the detection rates in cervical swab specimens were 36.2% for HPV-16, 15.5% for HPV-18 and 17.2% for HPV-52. During follow-up, 8 of 10 cervical cancer patients with viral DNA detected in blood within 3 months after treatment had recurrence, and a high percentage (87.5%, 7/8) of this recurrence involved distant metastases. Conclusions. In this study, real-time PCR detected HPV-16, -18 or -52 DNA in the peripheral blood of more than one-fourth of invasive cervical cancer patients. The association between risk of cancer recurrence and the amount of viral DNA detected in blood among cervical cancer patients after treatment is intriguing and deserves further investigation.

AB - Objective. To prospectively evaluate the feasibility of detecting human papillomavirus (HPV) type 16, 18 and 52 DNA in the peripheral blood of patients with cervical cancer using real-time polymerase chain reaction (PCR) and to determine its prognostic importance. Methods. Blood and cervical swab specimens from 135 consecutive patients with 60 invasive cervical cancers, 10 microinvasions, 20 cervical intraepithelial neoplasias (CIN) III, 10 CIN II, 10 CIN I and 25 controls were collected and examined for HPV type 16, 18 and 52 DNA using real-time PCR to investigate the prevalence and viral load of HPV DNA at the time of diagnosis and during follow-up in patients with positive blood samples. Results. Of the 60 patients with invasive cervical cancer, 27% had positive test results for HPV DNA in blood samples in contrast to 0% of patients with microinvasions, CIN III, CIN II, CIN I and normal controls. The DNA detection rates of viral subtypes in blood samples of cervical cancer patients were 5% for HPV-16, 16.7% for HPV-18, 8.3% for HPV-52, 1.7% for both HPV-16 and HPV-18 and 1.7% for both HPV-18 and HPV-52, while the detection rates in cervical swab specimens were 36.2% for HPV-16, 15.5% for HPV-18 and 17.2% for HPV-52. During follow-up, 8 of 10 cervical cancer patients with viral DNA detected in blood within 3 months after treatment had recurrence, and a high percentage (87.5%, 7/8) of this recurrence involved distant metastases. Conclusions. In this study, real-time PCR detected HPV-16, -18 or -52 DNA in the peripheral blood of more than one-fourth of invasive cervical cancer patients. The association between risk of cancer recurrence and the amount of viral DNA detected in blood among cervical cancer patients after treatment is intriguing and deserves further investigation.

KW - Cervical carcinoma

KW - Cervical neoplasia

KW - Metastasis

KW - Microinvasion

KW - Polymerase chain reaction

UR - http://www.scopus.com/inward/record.url?scp=28044449911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28044449911&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2005.07.004

DO - 10.1016/j.ygyno.2005.07.004

M3 - Article

C2 - 16099020

AN - SCOPUS:28044449911

VL - 99

SP - 615

EP - 621

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -